Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07234162 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 50 to 51 Interventions: Belinostat (Drug), Chidamide (Drug), Gemcitabine (Drug), Golidocitinib (Drug), Pralatrexate (Drug) to Chidamide (Drug), Gemcitabine (Drug), Golidocitinib (Drug) · Eligibility criteria revisedv2 Show 2 more changesShow less
    • Interventions: Belinostat (Drug), Chidamide (Drug), Gemcitabine (Drug), Golidocitinib (Drug), Pralatrexate (Drug) to Chidamide (Drug), Gemcitabine (Drug), Golidocitinib (Drug)
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
Trial Details
NCT Number NCT07234162
Lead Sponsor Dizal Pharmaceuticals
Conditions Peripheral T-cell Lymphoma
Enrollment 218 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov